Central Nervous System Lymphoma Clinical Trial
Official title:
A Phase I/II Study of Patients With Newly Diagnosed Primary Central Nervous System Lymphoma Treated With Methotrexate/BBBD, and Adding Rituximab (an Anti CD-20 Antibody) and Carboplatin, to the Treatment Regimen
Verified date | September 2021 |
Source | OHSU Knight Cancer Institute |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This phase I/II trial studies the side effects of methotrexate, mannitol, rituximab, and carboplatin and to see how well they work in treating patients with primary central nervous system lymphoma. Drugs used in chemotherapy, such as methotrexate and carboplatin, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Osmotic blood-brain barrier disruption uses mannitol to open the blood vessels around the brain and allow cancer-killing substances to be carried directly to the brain. Monoclonal antibodies, such as rituximab, may block cancer growth in different ways by targeting certain cells. Giving methotrexate, mannitol, rituximab, and carboplatin together may be an effective treatment for primary central nervous system lymphoma.
Status | Active, not recruiting |
Enrollment | 81 |
Est. completion date | January 31, 2023 |
Est. primary completion date | January 31, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: - Subjects with histopathologic confirmation of intermediate or high-grade primary central nervous system lymphoma (PCNSL) as documented by brain biopsy, or cytology (analysis from cerebral spinal fluid [CSF] or vitrectomy), and cluster of differentiation 20 (CD20) positive; whenever possible, the tumor should be characterized by immunophenotype - Subjects must be =< 90 days from diagnosis of PCNSL in the brain or spine; time from pathologic diagnosis to initiation of treatment should be specified; subjects with history of only ocular lymphoma are eligible if < 90 days since documented brain parenchymal disease (by imaging or by biopsy) - Subjects must have an Eastern Cooperative Oncology Group (ECOG) performance score =< 3 (Karnofsky >= 30) - Hematocrit >= 25% (may be reached by transfusion) (performed within 14 days of registration) - White blood cell count >= 2.5 x 10^3/mm^3 (performed within 14 days of registration) - Absolute granulocyte count >= 1.2 x 10^3/mm^3 (performed within 14 days of registration) - Platelets >= 100 x 10^3/mm^3 (or >= lower limit of institutional normal value) (performed within 14 days of registration) - Calculated creatinine clearance (Cr Cl) >= 50 ml/min (performed within 14 days of registration); eligible for full dose methotrexate - Calculated Cr Cl >= 30 ml/min (performed within 14 days of registration); eligible for reduced dose methotrexate - Bilirubin =< 2.0 x upper limit of institutional normal value (performed within 14 days of registration) - The subject may have had other systemic chemotherapy for PCNSL during the 90 days since PCNSL diagnosis; prior systemic chemotherapy must have been given at least 4 weeks prior to study entry (6 weeks for nitrosourea agents), with the exceptions of methotrexate and rituximab which may have been given at least 10 days prior; ocular lymphoma treatment may have been given any time prior to study entry; if the subject has undergone treatment for parenchymal disease and the parenchymal disease has progressed on a stable or increasing dose of steroids, the subject is not eligible for enrollment - Sexually active women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study treatment and for the duration of study treatment; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately - Subjects with a bone marrow biopsy which shows microscopic, low-level involvement of lymphoma are eligible - Subject with seropositivity for hepatitis B or hepatitis C must be cleared by hepatology service prior to participating in treatment protocol Exclusion Criteria: - Prior cranial or spinal radiotherapy - Subjects with radiographic signs of excessive intra-cranial mass effect with associated rapid neurologic deterioration, and/or spinal block, are unsafe to undergo BBBD chemotherapy and are not eligible - Uncontrolled (over the last 30 days), clinically significant confounding medical conditions - Seropositivity for the human immunodeficiency virus - Systemic lymphoma - Subjects who have a positive serum human chorionic gonadotropin (hCG), are pregnant or lactating are ineligible - Known allergy to any of the study agents - Subjects who are at significant risk for general anesthesia |
Country | Name | City | State |
---|---|---|---|
United States | Good Samaritan Hospital - Cincinnati | Cincinnati | Ohio |
United States | Cleveland Clinic Foundation | Cleveland | Ohio |
United States | Ohio State University Comprehensive Cancer Center | Columbus | Ohio |
United States | OHSU Knight Cancer Institute | Portland | Oregon |
Lead Sponsor | Collaborator |
---|---|
OHSU Knight Cancer Institute | National Cancer Institute (NCI), Oregon Health and Science University |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Incidence of toxicities, assessed using National Cancer Institute Common Toxicity Criteria for Adverse Events version 3.0 (Phase I) | Within 2 months of completion of study treatment | ||
Primary | CR rate (Phase II) | Within the first 3 months of treatment | ||
Secondary | Overall survival | Kaplan-Meier estimates of these survival distributions will be plotted. Descriptive stratifications of these survival distributions by baseline characteristics will be evaluated using the log-rank statistic. If there are multiple predictors of these outcomes, Cox proportional hazard models will be fit to these data to determine which predictors are independent of others in a multi-variable model. | From entry onto study until death from any cause, assessed at 2 years | |
Secondary | Event-free survival | Kaplan-Meier estimates of these survival distributions will be plotted. Descriptive stratifications of these survival distributions by baseline characteristics will be evaluated using the log-rank statistic. If there are multiple predictors of these outcomes, Cox proportional hazard models will be fit to these data to determine which predictors are independent of others in a multi-variable model. | From entry onto study until death or progression of disease, assessed at 2 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT04516655 -
A Phase II Trail of Chidamide ,Rituximab and Methotrexate in Lymphoma Patients
|
Phase 2 | |
Recruiting |
NCT05054426 -
Intermediate Dose of IV MTX as CNS Prophylaxis for High Risk DLBCL
|
Phase 3 | |
Recruiting |
NCT02623010 -
Bruton's Tyrosine Kinase Inhibitor Ibrutinib as Maintenance Treatment in Elderly Patients With Primary CNS Lymphoma
|
Phase 2 | |
Recruiting |
NCT04548648 -
A Pilot Study of Acalabrutinib in Relapsed/Refractory Primary and Secondary CNS Lymphomas
|
Phase 2 | |
Completed |
NCT03342586 -
Using a Novel Functional MRI Technique to Evaluate for Neurotoxicity
|
||
Terminated |
NCT02420795 -
Akt/ERK Inhibitor ONC201 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
|
Phase 1/Phase 2 | |
Completed |
NCT01011920 -
Trial for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma
|
Phase 2 | |
Completed |
NCT00967200 -
Study of Tissue Samples From Patients With Glioma or Other Brain Tumors
|
N/A | |
Recruiting |
NCT03684980 -
LTA Pilot Study of Glucarpidase in Patients With Central Nervous System Lymphoma
|
Early Phase 1 | |
Not yet recruiting |
NCT06213636 -
Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL).
|
Phase 1/Phase 2 | |
Recruiting |
NCT04938297 -
Rituximab,Zanubrutinib in Combination With Lenalidomide, Followed by Zanubrutinib or Lenalidomide Maintenance in Patients With Primary or Secondary CNS Lymphoma
|
Phase 2 | |
Recruiting |
NCT04792489 -
DALY II USA/ MB-CART2019.1 for DLBCL
|
Phase 2 | |
Completed |
NCT01458730 -
Nordic Study in Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma
|
Phase 2 | |
Completed |
NCT00153530 -
Whole Brain Irradiation in Primary Central Nervous System (CNS) Lymphoma (PCNSL)
|
Phase 4 | |
Recruiting |
NCT04186520 -
CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT05816746 -
Decitabine and Anti-PD-1 in R/R DLBCL
|
Phase 2 | |
Recruiting |
NCT06031194 -
Pharmacogenomics Effects on High-Dose Methotrexate Clearance in Patients With Diffuse Large B-Cell Lymphoma
|
||
Active, not recruiting |
NCT03962127 -
MIDNOR-STROKE- a Long Term Follow-up Study of Patients With First Ever Ischemic Stroke in Central Norway
|
||
Completed |
NCT03690895 -
Long-term Outcome of AIDS-related Primary Central Nervous System Lymphoma Treated With High Dose Methotrexate and Combined Antiretroviral Therapy
|
||
Recruiting |
NCT05114330 -
Secondary Central Nervous System Lymphoma Registry - Charité
|